Overview

This study explores the potential value of a new blood test approach for early detection of cancer.

Eligibility

Inclusion Criteria:

• Aim 1 Tissue
  • Cases:
    • Patient has a biopsy confirmed diagnosis of target histology
    • Tissue samples from synchronous or metachronous primary cancers may be used as long as they are clearly of a different target organ.
    • Tumors from patients with an underlying genetic disorder pre-disposing to cancer may be included as long as they are stratified from those without
  • Controls:
    • Patient does not have the diagnosis of target histology
• Aim 2 Blood
  • Cases:
    • Patient has a biopsy confirmed diagnosis of target histology or radiographic criteria that are unequivocal for diagnosis (example, meets radiographic criteria for hepatocellular carcinoma)
  • Controls:
    • Patient does not have a diagnosis of the target histology
• Aim 3 Urine
  • Cases:
    • Patient has a biopsy confirmed diagnosis of target histology or radiographic criteria that are unequivocal for diagnosis (example, meets radiographic criteria for hepatocellular carcinoma)
  • Controls:
    • Patient does not have a diagnosis of the target histology

Exclusion Criteria:

• Aim 1 Tissue
  • Cases and Controls:
    • Patient has had any transplants prior to tissue collection
    • Patient has received chemotherapy class drugs within 5 years prior to tissue collection
  • Cases:
    • Patient has had radiation to the current target lesion prior to tissue collection
    • Patient has multi-centric/multi-focal breast cancer with differing genetic profiles (ER/HER2/PR status differ; if multiple masses are present and not all are tested then exclude patient)
    • Patient has bilateral breast cancer/Ductal carcinoma in situ (DCIS)
• Aim 2 Blood
  • Cases and Controls:
    • Patient has known cancer outside of the target cancer 5 years prior to blood collection (not including basal cell or squamous cell skin cancers)
    • Patient has received chemotherapy class drugs in the 5 years prior to blood collection
    • Patient has had any prior radiation therapy to the target lesion prior to blood collection
    • Patient has had a biopsy to the target organ and/or lesion within 3 days before blood collection
  • Cases:
    • Patient has had an intervention to completely remove current target pathology
    • The current target pathology is a recurrence
    • Patient has multi-centric/multi-focal breast cancer with differing genetic profiles (ER/HER2/PR status differ; if multiple masses are present and not all are tested then exclude patient)
    • Patient has bilateral breast cancer/DCIS
• Aim 3 Urine
  • Patient has known cancer outside of the target cancer 5 years prior to urine collection (not including basal cell or squamous cell skin cancers)
  • Patient has received chemotherapy class drugs in the 5 years prior to urine collection
  • Patient has had any prior radiation therapy to the target lesion prior to urine collection
  • Patient has had a biopsy to the target organ and/or lesion within 3 days before urine collection
  • The current target pathology is a recurrence
  • Patient has chronic indwelling urinary catheter
  • Patient has had a urinary tract infection within the 14 days prior to sample collection
  • If patient does not have a primary bladder, ureter or urethral cancer, patient has a history of bladder ureter, or urethral cancer
  • Cases:
    • Patient has had an intervention to completely remove current target pathology
    • The current target pathology is a recurrence
    • Patient has multi-centric/multi-focal breast cancer with differing genetic profiles [estrogen receptor (ER)/human epidermal growth factor receptor 2 (HER2)/progesterone receptor (PR)] status differ; if multiple masses are present and not all are tested then exclude patient)
    • Patient has bilateral breast cancer/DCIS